Advertisement

HDL Structure, Function, and Antiinflammatory Properties

Chapter

Abstract

The high density lipoproteins (HDL) in human plasma are structurally and functionally diverse. They consist of numerous subpopulations of particles that are continually being interconverted from one to another. There is compelling evidence from epidemiological and animal studies that HDL protect against cardiovascular disease. The cardioprotective properties of HDL have largely been attributed to their role in reverse cholesterol transport. However, HDL also have antioxidant, antiinflammatory, and antithrombotic properties that contribute to their cardioprotective effects. This chapter focuses on the antiinflammatory functions of HDL and what is known about the ability of specific HDL subpopulations to inhibit acute and chronic vascular inflammation.

Keywords

HDL Structure Remodelling ApoA-I Inflammation 

Notes

Acknowledgments

This work was funded by NHMRC Program Grant 482800.

References

  1. 1.
    Gordon DJ, Probstfield JL, Garrison RJ et al (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8–15PubMedGoogle Scholar
  2. 2.
    Morehouse LA, Sugarman ED, Bourassa PA et al (2007) Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 48:1263–1272CrossRefPubMedGoogle Scholar
  3. 3.
    Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ (1999) Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100:1816–1822PubMedGoogle Scholar
  4. 4.
    Lewis GF, Rader DJ (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96:1221–1232CrossRefPubMedGoogle Scholar
  5. 5.
    Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre R (2006) Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 41:1031–1040CrossRefPubMedGoogle Scholar
  6. 6.
    Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ (2006) High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 26:1144–1149CrossRefPubMedGoogle Scholar
  7. 7.
    Mineo C, Deguchi H, Griffin JH, Shaul PW (2006) Endothelial and antithrombotic actions of HDL. Circ Res 98:1352–1364CrossRefPubMedGoogle Scholar
  8. 8.
    Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ (1995) High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15:1987–1994PubMedGoogle Scholar
  9. 9.
    Murphy AJ, Woollard KJ, Hoang A et al (2008) High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 28:2071–2077CrossRefPubMedGoogle Scholar
  10. 10.
    Blanche PJ, Gong EL, Forte TM, Nichols AV (1981) Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 665:408–419PubMedGoogle Scholar
  11. 11.
    Cheung MC, Albers JJ (1984) Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 259:12201–12209PubMedGoogle Scholar
  12. 12.
    Huang Y, von Eckardstein A, Wu S, Maeda N, Assmann G (1994) A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA 91:1834–1838CrossRefPubMedGoogle Scholar
  13. 13.
    Rye KA, Barter PJ (2004) Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24:421–428CrossRefPubMedGoogle Scholar
  14. 14.
    Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA (2005) Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res 46:896–903CrossRefPubMedGoogle Scholar
  15. 15.
    Rye KA, Hime NJ, Barter PJ (1995) The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins. J Biol Chem 270:189–196CrossRefPubMedGoogle Scholar
  16. 16.
    Brown ML, Inazu A, Hesler CB et al (1989) Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342:448–451CrossRefPubMedGoogle Scholar
  17. 17.
    Ishigami M, Yamashita S, Sakai N et al (1994) Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem 116:257–262PubMedGoogle Scholar
  18. 18.
    Settasatian N, Duong M, Curtiss LK et al (2001) The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 276:26898–26905CrossRefPubMedGoogle Scholar
  19. 19.
    van Haperen R, Samyn H, Moerland M et al (2008) Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS One 3:e2255CrossRefPubMedGoogle Scholar
  20. 20.
    Valenta DT, Ogier N, Bradshaw G et al (2006) Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol 26:1572–1578CrossRefPubMedGoogle Scholar
  21. 21.
    Clay MA, Newnham HH, Barter PJ (1991) Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler Thromb 11:415–422PubMedGoogle Scholar
  22. 22.
    Jaye M, Lynch KJ, Krawiec J et al (1999) A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 21:424–428CrossRefPubMedGoogle Scholar
  23. 23.
    Rye KA, Wee K, Curtiss LK, Bonnet DJ, Barter PJ (2003) Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation. J Biol Chem 278:22530–22536CrossRefPubMedGoogle Scholar
  24. 24.
    Rye KA, Duong M, Psaltis MK et al (2002) Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling. Biochemistry 41:12538–12545CrossRefPubMedGoogle Scholar
  25. 25.
    Caiazza D, Jahangiri A, Rader DJ, Marchadier D, Rye KA (2004) Apolipoproteins regulate the kinetics of endothelial lipase-mediated hydrolysis of phospholipids in reconstituted high-density lipoproteins. Biochemistry 43:11898–11905CrossRefPubMedGoogle Scholar
  26. 26.
    Hime NJ, Barter PJ, Rye KA (1998) The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J Biol Chem 273:27191–27198CrossRefPubMedGoogle Scholar
  27. 27.
    Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ (2008) Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 57:77–83CrossRefPubMedGoogle Scholar
  28. 28.
    Luc G, Bard JM, Ferrieres J et al (2002) Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 22:1155–1161CrossRefPubMedGoogle Scholar
  29. 29.
    Brousseau ME, Schaefer EJ, Wolfe ML et al (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350:1505–1515CrossRefPubMedGoogle Scholar
  30. 30.
    Nissen SE, Tardif JC, Nicholls SJ et al (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1304–1316CrossRefPubMedGoogle Scholar
  31. 31.
    Bots ML, Visseren FL, Evans GW et al (2007) Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370:153–160CrossRefPubMedGoogle Scholar
  32. 32.
    Barter PJ, Caulfield M, Eriksson M et al (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122CrossRefPubMedGoogle Scholar
  33. 33.
    Ibanez B, Vilahur G, Cimmino G et al (2008) Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 51:1104–1109CrossRefPubMedGoogle Scholar
  34. 34.
    Parolini C, Marchesi M, Lorenzon P et al (2008) Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 51:1098–1103CrossRefPubMedGoogle Scholar
  35. 35.
    Nissen SE, Tsunoda T, Tuzcu EM et al (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292–2300CrossRefPubMedGoogle Scholar
  36. 36.
    Rong JX, Li J, Reis ED et al (2001) Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104:2447–2452CrossRefPubMedGoogle Scholar
  37. 37.
    Spieker LE, Sudano I, Hurlimann D et al (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399–1402CrossRefPubMedGoogle Scholar
  38. 38.
    Drew BG, Duffy SJ, Formosa MF et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119:2103–2111CrossRefPubMedGoogle Scholar
  39. 39.
    Tardif JC, Gregoire J, L’Allier PL et al (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297:1675–1682CrossRefPubMedGoogle Scholar
  40. 40.
    Nicholls SJ, Cutri B, Worthley SG et al (2005) Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25:2416–2421CrossRefPubMedGoogle Scholar
  41. 41.
    Navab M, Anantharamaiah GM, Reddy ST et al (2004) Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109:3215–3220CrossRefPubMedGoogle Scholar
  42. 42.
    Wool GD, Vaisar T, Reardon CA, Getz GS (2009) An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J Lipid Res 50:1889–1900CrossRefPubMedGoogle Scholar
  43. 43.
    Nicholls SJ, Dusting GJ, Cutri B et al (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111:1543–1550CrossRefPubMedGoogle Scholar
  44. 44.
    Calabresi L, Franceschini G, Sirtori CR et al (1997) Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 238:61–65CrossRefPubMedGoogle Scholar
  45. 45.
    Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR (1999) High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 274:33143–33147CrossRefPubMedGoogle Scholar
  46. 46.
    Park SH, Park JH, Kang JS, Kang YH (2003) Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol 35:168–182CrossRefPubMedGoogle Scholar
  47. 47.
    McGrath KC, Li XH, Puranik R et al (2009) Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 29:877–882CrossRefPubMedGoogle Scholar
  48. 48.
    Navab M, Imes SS, Hama SY et al (1991) Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88:2039–2046CrossRefPubMedGoogle Scholar
  49. 49.
    Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ (1998) Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 18:1450–1455PubMedGoogle Scholar
  50. 50.
    Dimayuga P, Zhu J, Oguchi S et al (1999) Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 264:465–468CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Lipid Research GroupThe Heart Research InstituteSydneyAustralia
  2. 2.Faculty of MedicineUniversity of SydneySydneyAustralia
  3. 3.Department of MedicineUniversity of MelbourneMelbourneAustralia

Personalised recommendations